Alnylam Pharmaceuticals (ALNY) Key Value Driver Entering Phase 2 - Jefferies
Tweet Send to a Friend
Jefferies analyst Maury Raycroft reiterated a Buy rating and $193.00 price target on Alnylam Pharmaceuticals (NASDAQ: ALNY) on the belief ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE


